GSK's ViiV touts 2-month HIV data as sister injection Cabenuva awaits FDA redemption

After the FDA rejected its once-monthly HIV injection Cabenuva in December, GlaxoSmithKline’s keeping the talk going about its long-acting options. Now, it has rolled out detailed data showing a sister version designed to be given every two months works as well.